The role of C-C chemokines and their receptors in osteoarthritis

Arthritis Rheum. 2001 May;44(5):1056-70. doi: 10.1002/1529-0131(200105)44:5<1056::AID-ANR186>3.0.CO;2-U.

Abstract

Objective: To evaluate the involvement of the chemokine/chemokine receptor system in cartilage degradation in osteoarthritis (OA).

Methods: Expression of the 4 C-C chemokines monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and RANTES, and their receptors CCR-2 and CCR-5, was assessed in 11 OA patients and 5 normal controls, by reverse transcriptase-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), immunochemistry, and flow cytometry on untreated or interleukin-1beta (IL-1beta)- and/or tumor necrosis factor alpha (TNFalpha)-stimulated chondrocytes. The effects of these chemokines on the expression of matrix metalloproteinases (MMP) and tissue inhibitor of metalloproteinases were assayed by RT-PCR and ELISA. The effects on proteoglycan synthesis and release were also assayed, using 35S-sulfate incorporation and 35S-proteoglycan release.

Results: The C-C chemokines and their receptors CCR-2 and CCR-5 were found to be expressed in normal and OA chondrocytes. However, regulation of chemokine expression by IL-1beta and TNFalpha differed between normal and OA chondrocytes. Intracellular staining revealed that approximately 20% of the chondrocytes contained CCR-2 and CCR-5 in the cytoplasm, whereas cell surface expression was detected less frequently. Interestingly, RANTES induced expression of its own receptor, CCR-5, suggesting an autocrine/paracrine pathway of the chemokine within the cartilage milieu. Finally, addition of MCP-1 or RANTES not only induced MMP-3 expression, but also inhibited proteoglycan synthesis and enhanced proteoglycan release from the chondrocytes.

Conclusion: The differential expression of chemokines and their receptors under the regulation of IL-1beta and TNFalpha suggests that the cytokine-triggered chemokine system may play a key role in the cartilage degradation of OA, possibly acting in an autocrine/paracrine manner.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cartilage / immunology
  • Cartilage / metabolism
  • Chemokine CCL2 / analysis
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / immunology*
  • Chemokine CCL5 / analysis
  • Chemokine CCL5 / genetics
  • Chemokine CCL5 / immunology*
  • Chondrocytes / drug effects
  • Chondrocytes / immunology
  • Chondrocytes / metabolism
  • DNA Primers
  • Flow Cytometry
  • Gene Expression / drug effects
  • Gene Expression / immunology
  • Humans
  • Interleukin-1 / pharmacology
  • Matrix Metalloproteinase 3 / genetics
  • Matrix Metalloproteinase 9 / genetics
  • Middle Aged
  • Osteoarthritis / immunology*
  • Proteoglycans / metabolism
  • RNA, Messenger / analysis
  • Receptors, CCR2
  • Receptors, CCR5 / genetics
  • Receptors, CCR5 / immunology
  • Receptors, Chemokine / genetics
  • Receptors, Chemokine / immunology*
  • Tissue Inhibitor of Metalloproteinase-1 / genetics
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • CCR2 protein, human
  • Chemokine CCL2
  • Chemokine CCL5
  • DNA Primers
  • Interleukin-1
  • Proteoglycans
  • RNA, Messenger
  • Receptors, CCR2
  • Receptors, CCR5
  • Receptors, Chemokine
  • Tissue Inhibitor of Metalloproteinase-1
  • Tumor Necrosis Factor-alpha
  • Matrix Metalloproteinase 3
  • Matrix Metalloproteinase 9